This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following Patents and Patent Applications to Etubics Corporation (``Etubics'') located in San Francisco, California, USA.
Document
Prospective Grant of Exclusive Patent License: Development and Commercialization of Adeno-Virus Based Cancer Immunotherapy
This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
81 FR 31650
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Prospective Grant of Exclusive Patent License: Development and Commercialization of Adeno-Virus Based Cancer Immunotherapy,” thefederalregister.org (May 19, 2016), https://thefederalregister.org/documents/2016-11770/prospective-grant-of-exclusive-patent-license-development-and-commercialization-of-adeno-virus-based-cancer-immunotherap.